CIARDIELLO, DAVIDE
 Distribuzione geografica
Continente #
EU - Europa 2.497
AS - Asia 1.204
NA - Nord America 1.097
SA - Sud America 116
Continente sconosciuto - Info sul continente non disponibili 68
AF - Africa 13
Totale 4.995
Nazione #
RU - Federazione Russa 1.909
US - Stati Uniti d'America 1.071
SG - Singapore 430
CN - Cina 271
IT - Italia 225
HK - Hong Kong 189
IE - Irlanda 152
VN - Vietnam 125
BR - Brasile 94
DE - Germania 80
KR - Corea 63
IN - India 48
GB - Regno Unito 33
JP - Giappone 25
FR - Francia 21
CA - Canada 16
FI - Finlandia 16
AT - Austria 14
PK - Pakistan 14
NL - Olanda 13
PL - Polonia 11
EC - Ecuador 7
MX - Messico 7
CZ - Repubblica Ceca 6
AR - Argentina 5
TR - Turchia 5
CO - Colombia 4
ID - Indonesia 4
IQ - Iraq 4
MA - Marocco 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
BD - Bangladesh 3
PH - Filippine 3
SE - Svezia 3
BO - Bolivia 2
CL - Cile 2
DO - Repubblica Dominicana 2
ES - Italia 2
GI - Gibilterra 2
GR - Grecia 2
JO - Giordania 2
KE - Kenya 2
TH - Thailandia 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BE - Belgio 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 4.927
Città #
Moscow 708
San Jose 234
Singapore 230
Hong Kong 184
Dublin 146
Santa Clara 133
Ashburn 85
Naples 82
Chandler 67
Seoul 62
Hefei 59
Beijing 49
New York 47
Ho Chi Minh City 41
Munich 40
Los Angeles 39
Council Bluffs 37
Dallas 34
Bengaluru 32
Hanoi 30
Haiphong 12
Bremen 11
Princeton 9
Rawalpindi 9
Roxbury 9
São Paulo 9
The Dalles 9
Turku 9
Warsaw 9
Da Nang 8
San Francisco 8
Cambridge 7
Frankfurt am Main 7
Vienna 7
Amsterdam 6
Changsha 6
London 6
Milan 6
Nuremberg 6
Shanghai 6
Atlanta 5
Aversa 5
Boardman 5
Giugliano in Campania 5
Lappeenranta 5
Manchester 5
Montreal 5
Orem 5
Piscataway 5
Brooklyn 4
Caserta 4
Chennai 4
Chicago 4
Elora 4
Ercolano 4
Falkenstein 4
Hillsboro 4
Hải Dương 4
Mumbai 4
Tokyo 4
Baku 3
Bari 3
Battipaglia 3
Belo Horizonte 3
Berlin 3
Boston 3
Brno 3
Buffalo 3
Central 3
City of London 3
Colle di Val d'Elsa 3
Guayaquil 3
Istanbul 3
Mexico City 3
Montpellier 3
Nha Trang 3
Quito 3
Rio de Janeiro 3
San Diego 3
Sant'Antimo 3
Seattle 3
Shenzhen 3
Tianjin 3
Afragola 2
Amman 2
Anantapur 2
Andover 2
Anápolis 2
Baghdad 2
Bangkok 2
Barcellona Pozzo di Gotto 2
Bogotá 2
Bologna 2
Botucatu 2
Brdo 2
Bắc Giang 2
Campo Grande 2
Canoas 2
Castellammare di Stabia 2
Cercola 2
Totale 2.690
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 163
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 163
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 160
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 153
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Clinical management of metastatic colorectal cancer in the era of precision medicine 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 148
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 147
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review 145
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 141
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 140
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 129
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 127
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 126
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 125
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 120
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 117
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 115
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 111
Targeting the EGFR signalling pathway in metastatic colorectal cancer 89
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer 32
MRI-based radiomics for preoperative T-staging of rectal cancer: a retrospective analysis 16
BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives 16
Clinical activity and safety of nivolumab in combination with ipilimumab in metastatic melanoma: findings from REALIPINIVO, a real-world study 7
Totale 4.995
Categoria #
all - tutte 15.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202268 0 2 1 1 5 0 0 0 2 3 30 24
2022/2023321 19 6 9 28 31 27 3 24 146 4 20 4
2023/2024226 22 8 8 14 47 48 7 5 8 6 21 32
2024/2025784 27 27 26 56 108 117 80 77 84 62 64 56
2025/20263.487 174 187 162 101 326 1.798 206 183 133 92 71 54
2026/202799 27 72 0 0 0 0 0 0 0 0 0 0
Totale 4.995